Updates matching "Access to Biomarker Testing"

This week, New Jersey lawmakers approved legislation to improve access to biomarker testing with a unanimous vote by the Assembly Appropriations Committee. Assembly Bill 4163 now awaits a vote on the Assembly floor. The Senate advanced identical legislation (Senate Bill 3098) in the Senate Commerce Committee last week, which now awaits further consideration by the Senate Budget & Appropriations Committee. Advocates with the New Jersey Biomarker Testing Coalition are hopeful that the bills will receive the necessary support to secure swift passage in the new year.

Earlier today, Senate Bill 3098 was unanimously voted out of the Senate Commerce Committee. This legislation, which aims to ensure that biomarker testing is covered by Medicaid and all other state-regulated insurance plans when patients need it, now advances to the Senate Budget & Appropriations Committee for further consideration. In October, the Assembly Financial Institutions & Insurance Committee approved identical legislation (Assembly Bill 4163), which now awaits a hearing in the Assembly Appropriations Committee.

Key public health, patient and provider groups have come out in support of improving access to biomarker testing in New Jersey, urging lawmakers to advance and pass Assembly Bill 4163 / Senate Bill 3098 this legislative session. This fall, a broad coalition of over 30 organizations, medical leaders and patient advocates wrote to members of the Assembly Financial Institutions & Insurance (AFI) Committee to vote in favor of A4163, which they did—unanimously—several weeks ago. Now, the New Jersey Biomarker Coalition is looking to the Assembly Appropriations and Senate Commerce Committees to take up this bill and follow the lead of their AFI member colleagues.

Today, the Assembly Financial Institutions & Insurance Committee voted to improve New Jerseyans’ access to biomarker testing, advancing Assembly Bill 4163 out of committee. Championed by Assemblymembers Shavonda Sumter, Gary Schaer and Shama Haider, the proposal would ensure biomarker testing is covered by New Jersey-regulated insurance plans, including Medicaid, when medical and scientific evidence shows it would provide a benefit to patients. Advocates now look to the full Assembly to favorably advance Assembly Bill 4163 to the Senate.

The American Cancer Society (ACS) released an update this week on breast cancer occurrence and trends in the United States. While the new report finds mortality rates have dropped by 44% since 1989, not all women have benefited from this progress. The report highlighted a continued upward trend in breast cancer incidence with the steepest increase in women younger than 50 years and Asian American/Pacific Islander (AAPI) women of all ages. The release coincides with the American Cancer Society Cancer Action Network’s (ACS CAN) campaign to connect patients with the right treatment at the right time through increasing access to biomarker testing in Hawaii.

Harrisburg residents and cancer advocates gathered at the Pennsylvania War Veterans’ Memorial Fountain outside of the Capitol building in Harrisburg this evening to honor the lives affected by cancer with a heartfelt display of 270 Lights of Hope bags representing the estimated 27,000 Pennsylvanians who will die from the disease in 2024. The personalized Lights of Hope bags were lined along the fountain, which was lit pink for Breast Cancer Awareness Month, to symbolize the strength, hope and memories of those touched by cancer.

Gov. Gavin Newsom signed the state budget on June 29, allowing for Medi-Cal implementation of Senate Bill 496. Starting July 1st, Medi-Cal and other state-regulated health insurance plans will cover comprehensive biomarker testing when supported by medical and scientific evidence.

Today, Governor Shapiro signed House Bill 1754 into law, securing a major win for patients across Pennsylvania. The new law will require all state-regulated health plans, including Medicaid, to cover comprehensive biomarker testing, which will enable more Pennsylvanians to access biomarker testing that can open the door to precision medicine. Targeted treatment can lead to fewer side effects, improved survival, better quality of life and potentially lower costs for patients facing cancer and other serious illnesses.

Cancer Advocates Applauds the House’s Passage of Biomarker Testing Legislation, Ensuring Ohioans Have Better Access to Personalized Care.